1-(5-Chloro-2-hydroxyphenyl)-3-naphthalen-1-ylurea

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-(5-Chloro-2-hydroxyphenyl)-3-naphthalen-1-ylurea
• 化学式: C₁₇H₁₃ClN₂O₂
• 分子量: 312.7
• InChiKey: BAEYRKAIHHEUNE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  61.4
• 氢给体数：
  3
• 氢受体数：
  2

文献信息

• The use of substituted carbocyclic compounds as rotamases inhibitors
  申请人：Jerini AG

  公开号：EP1402888A1

  公开（公告）日：2004-03-31

  The present invention is related to the use of a compound as an inhibitor to a rotamase, whereby the compound has the structure:         A-X-Y     (I) wherein A is cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl; X is a spacer and is selected from X1 or X2, wherein X1 is selected from the group comprising -[(CRaRb)n-NRc-CO-NRd-(CRaRb)m]t-, -[(CRaRb)n-NRc-CS-NRd-(CRaRb)m]t-, -[(CRaRb)n-NRc-C(N-CN)-NRd-(CRaRb)m]t-, -[(CRaRb)n-NRc-C(N-Re)-NRd-(CRaRb)m]t-, -[(CRaRb)n-CO-NRc-(CRaRb)m]t-, -[(CRaRb)n-NRc-(CRaRb)m]t-, -[(CRaRb)n-NRc-CO-O-(CRaRb)m]t-, -[(CRaRb)n-O-CO-NRc-(CRaRb)m]t-, -[(CRaRb)n-O-(CRaRb)m]t-, -[(CRaRb)n-SRc-(CRaRb)m]t-; wherein X2 is selected from the group comprising - [(CRaRb)n-CO-(CRaRb)m]t-, -[(CRaRb)n-CS-(CRaRb)m]t-, -[(CRaRb)n-NRc-CO-(CRaRb)m]t-, -[(CRaRb)n-CO-NRc-(CRaRb)m]t-, -[(CRaRb)n-NRc-CS-(CRaRb)m]t-, -[(CRaRb)n-CS-NRc-(CRaRb)m]t-, -[(CRaRb)n-NRc-SO2-(CRaRb)m]t-, -[(CRaRb)n-SO2-NRc-(CRaRb)m]t-, -[(CRaRb)n-SO-(CRaRb)m]t-, -[(CRaRb)n-SO2-(CRaRb)m]t-, -[(CRaRb)n]t-; wherein n and m are independently selected from each other and are any integer between 0 and 10 provided that if n is 0, m is different from 0, and if m is 0, n is different from 0; wherein t is independently selected from n and/or m and is any integer between 0 and 10; wherein Ra, Rb, Rc, Rd and Re are independently from each other selected from the group comprising H, alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein Y is selected from the group comprising alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclyl, substituted heterocyclyl, mono-unsaturated heterocyclyl, poly-unsaturated heterocyclyl, mono-substituted poly-unsaturated heterocyclyl, poly-substituted poly-unsaturated heterocyclyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl, wherein Y is different from a peptide.

  本发明涉及将某种化合物作为旋转酶的抑制剂使用，其中该化合物具有以下结构：        A-X-Y     (I)其中A为环烷基、取代环烷基、杂环烷基、取代杂环烷基、芳基、取代芳基、杂芳基或取代杂芳基；X为间隔物，可从X1或X2中选择，其中X1可从以下组中选择：-[(CRaRb)n-NRc-CO-NRd-(CRaRb)m]t-，-[(CRaRb)n-NRc-CS-NRd-(CRaRb)m]t-，-[(CRaRb)n-NRc-C(N-CN)-NRd-(CRaRb)m]t-，-[(CRaRb)n-NRc-C(N-Re)-NRd-(CRaRb)m]t-，-[(CRaRb)n-CO-NRc-(CRaRb)m]t-，-[(CRaRb)n-NRc-(CRaRb)m]t-，-[(CRaRb)n-NRc-CO-O-(CRaRb)m]t-，-[(CRaRb)n-O-CO-NRc-(CRaRb)m]t-，-[(CRaRb)n-O-(CRaRb)m]t-，-[(CRaRb)n-SRc-(CRaRb)m]t-；其中X2可从以下组中选择：-[(CRaRb)n-CO-(CRaRb)m]t-，-[(CRaRb)n-CS-(CRaRb)m]t-，-[(CRaRb)n-NRc-CO-(CRaRb)m]t-，-[(CRaRb)n-CO-NRc-(CRaRb)m]t-，-[(CRaRb)n-NRc-CS-(CRaRb)m]t-，-[(CRaRb)n-CS-NRc-(CRaRb)m]t-，-[(CRaRb)n-NRc-SO2-(CRaRb)m]t-，-[(CRaRb)n-SO2-NRc-(CRaRb)m]t-，-[(CRaRb)n-SO-(CRaRb)m]t-，-[(CRaRb)n-SO2-(CRaRb)m]t-，-[(CRaRb)n]t-；其中n和m相互独立选择，为0到10之间的任意整数，条件是如果n为0，则m与0不同，如果m为0，则n与0不同；其中t从n和/或m中独立选择，为0到10之间的任意整数；其中Ra、Rb、Rc、Rd和Re相互独立选择，可从H、烷基、环烷基、芳基、杂芳基和杂环烷基中选择；Y可从烷基、取代烷基、环烷基、取代环烷基、环烯基、取代环烯基、杂环烷基、取代杂环烷基、单不饱和杂环烷基、多不饱和杂环烷基、单取代多不饱和杂环烷基、多取代多不饱和杂环烷基、芳基、取代芳基、杂芳基和取代杂芳基中选择，其中Y与肽不同。
• New compounds for the inhibition of undesired cell proliferation and use thereof
  申请人：Jerini AG

  公开号：EP1402887A1

  公开（公告）日：2004-03-31

  The present invention is related to the use of a compound for the manufacture of a medicament for the treatment of a disease, whereby the disease involves an abnormal cell proliferation, an undesired cell proliferation, an abnormal mitosis and/or an undesired mitosis. whereby the compound has the structure:         A-X-Y     (I) wherein A is cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl; X is a spacer and is selected from X1 or X2, wherein X1 is selected from the group comprising -[(CRaRb)n-NRc-CO-NRd-(CRaRb)m]t-, [(CRaRb)n-NRc-CS-NRd-(CRaRb)m]t-, -[(CRaRb)n-NRc-C(N-CN)-NRd-(CRaRb)m]t-, -[(CRaRb)n-NRc-C(N-Re)-NRd-(CRaRb)m]t-, -[(CRaRb)n-CO-NRc-(CRaRb)m]t-, -[(CRaRb)n-NRc-(CRaRb)m]t-, -[(CRaRb)n-NRc-CO-O-(CRaRb)m]t-, -[(CRaRb)n-O-CO-NRc-(CRaRb)m]t-, -[(CRaRb)n-O-(CRaRb)m]t-, -[(CRaRb)n-SRc-(CRaRb)m]t-; wherein X2 is selected from the group comprising -[(CRaRb)n-CO-(CRaRb)m]t-, -[(CRaRb)n-CS-(CRaRb)m]t-, -[(CRaRb)n-NRc-CO-(CRaRb)m]t-, -[(CRaRb)n-CO-NRc-(CRaRb)m]t-, -[(CRaRb)n-NRc-CS-(CRaRb)m]t-, -[(CRaRb)n-CS-NRc-(CRaRb)m]t-, -[(CRaRb)n-NRc-SO2-(CRaRb)m]t-, -[(CRaRb)n-SO2-NRc-(CRaRb)m]t-, -[(CRaRb)n-SO-(CRaRb)m]t-, -[(CRaRb)n-SO2-(CRaRb)m]t-, -[(CRaRb)n]t-; wherein n and m are independently selected from each other and are any integer between 0 and 10 provided that if n is 0, m is different from 0, and if m is 0, n is different from 0; wherein t is independently selected from n and/or m and is any integer between 0 and 10; wherein Ra, Rb, Rc, Rd and Re are independently from each other selected from the group comprising H, alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and wherein Y is selected from the group comprising alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclyl, substituted heterocyclyl, mono-unsaturated heterocyclyl, poly-unsaturated heterocyclyl, mono-substituted poly-unsaturated heterocyclyl, poly-substituted poly-unsaturated heterocyclyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl, wherein Y is different from a peptide.

  本发明涉及一种化合物用于制造治疗疾病的药物，其中该疾病涉及异常细胞增殖、不良细胞增殖、异常有丝分裂和/或不良有丝分裂，其中该化合物具有以下结构：A-X-Y（I），其中A为环烷基、取代环烷基、杂环烷基、取代杂环烷基、芳香族、取代芳香族、杂芳香族或取代杂芳香族；X为间隔物，选择自X1或X2，其中X1选择自包括-[(CRaRb)n-NRc-CO-NRd-(CRaRb)m]t-、[(CRaRb)n-NRc-CS-NRd-(CRaRb)m]t-、-[(CRaRb)n-NRc-C(N-CN)-NRd-(CRaRb)m]t-、-[(CRaRb)n-NRc-C(N-Re)-NRd-(CRaRb)m]t-、-[(CRaRb)n-CO-NRc-(CRaRb)m]t-、-[(CRaRb)n-NRc-(CRaRb)m]t-、-[(CRaRb)n-NRc-CO-O-(CRaRb)m]t-、-[(CRaRb)n-O-CO-NRc-(CRaRb)m]t-、-[(CRaRb)n-O-(CRaRb)m]t-、-[(CRaRb)n-SRc-(CRaRb)m]t-；其中X2选择自包括-[(CRaRb)n-CO-(CRaRb)m]t-、-[(CRaRb)n-CS-(CRaRb)m]t-、-[(CRaRb)n-NRc-CO-(CRaRb)m]t-、-[(CRaRb)n-CO-NRc-(CRaRb)m]t-、-[(CRaRb)n-NRc-CS-(CRaRb)m]t-、-[(CRaRb)n-CS-NRc-(CRaRb)m]t-、-[(CRaRb)n-NRc-SO2-(CRaRb)m]t-、-[(CRaRb)n-SO2-NRc-(CRaRb)m]t-、-[(CRaRb)n-SO-(CRaRb)m]t-、-[(CRaRb)n-SO2-(CRaRb)m]t-、-[(CRaRb)n]t-；其中n和m彼此独立选择且为0和10之间的任意整数，条件是如果n为0，则m不等于0，如果m为0，则n不等于0；其中t独立选择自n和/或m，为0和10之间的任意整数；其中Ra、Rb、Rc、Rd和Re独立于彼此选择自包括H、烷基、环烷基、芳香族、杂芳香族和杂环烷基；Y选择自包括烷基、取代烷基、环烷基、取代环烷基、环烷烯基、取代环烷烯基、杂环烷基、取代杂环烷基、单不饱和杂环烷基、多不饱和杂环烷基、单取代多不饱和杂环烷基、多取代多不饱和杂环烷基、芳香族、取代芳香族、杂芳香族和取代杂芳香族，其中Y与肽不同。
• Phenol derivatives and their use as rotamase inhibitors
  申请人：Knolle Jochen

  公开号：US20070054904A1

  公开（公告）日：2007-03-08

  The present invention is related to a compound of the formula (I), (II), (III), (IV), (V): wherein Z 1 , Z 2 , Z 3 and Z 4 are each and independently selected from the group comprising C(O)—, —C(S)—, —C(O)—NR 10 —, —C(S)—NR 11 —, —C(N—CN)—NR 12 —, —S(O)—, —S(O 2 )—, —S(O)—NR 13 —, and —S(O 2 )—NR 14 —, —O—, —S— or are each and individually absent; X is a spacer and is independently selected from the group comprising -M1-L1-K-L2-M2-, wherein Y. is selected from the group comprising alkyl, substituted alkyl, straight alkyl, substituted straight alkyl, branched alkyl, substituted branched alkyl, straight alkenyl, substituted straight alkenyl, branched alkenyl, substituted branched alkenyl, straight alkynyl, substituted straight alkynyl, branched alkynyl, substituted branched alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclyl, substituted heterocyclyl, mono-unsaturated heterocyclyl, poly-unsaturated heterocyclyl, mono-substituted poly-unsaturated heterocyclyl, poly-substituted poly-unsaturated heterocyclyl, mono-substituted mono-unsaturated heterocyclyl, poly-substituted mono-unsaturated heterocyclyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl, wherein Y is different from a peptide or is absent.

  本发明涉及以下化合物的公式(I)、(II)、(III)、(IV)、(V)： 其中，Z1、Z2、Z3和Z4分别且独立地选自包括C(O)、-C(S)-、-C(O)-NR10-、-C(S)-NR11-、-C(N-CN)-NR12-、-S(O)-、-S(O2)-、-S(O)-NR13-和-S(O2)-NR14-、-O-、-S-的基团，或者它们各自单独不存在；X是一个间隔符，可以独立地选自-M1-L1-K-L2-M2-的基团，其中Y选自包括烷基、取代烷基、直链烷基、取代直链烷基、支链烷基、取代支链烷基、直链烯基、取代直链烯基、支链烯基、取代支链烯基、直链炔基、取代直链炔基、支链炔基、取代支链炔基、环烷基、取代环烷基、环烯基、取代环烯基、杂环基、取代杂环基、单不饱和杂环基、多不饱和杂环基、单取代多不饱和杂环基、多取代多不饱和杂环基、单取代单不饱和杂环基、多取代单不饱和杂环基、芳基、取代芳基、杂芳基和取代杂芳基，其中Y不同于肽或不存在。
• COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF
  申请人：KNOLLE Jochen

  公开号：US20110065760A1

  公开（公告）日：2011-03-17

  The present invention is related to a compound of the formula (I), (II), (III), (IV), (V): wherein Z 1 , Z 2 , Z 3 and Z 4 are each and independently selected from the group comprising C(O)—, —C(S)—, —C(O)—NR 10 —, —C(S)—NR 11 —, —C(N—CN)—NR 12 —, —S(O)—, —S(O 2 )—, —S(O)—NR 13 —, and S(O 2 )—NR 14 —, —O—, —S— or are each and individually absent; X is a spacer and is independently selected from the group comprising -M1-L1-K-L2-M2-, wherein Y. is selected from the group comprising alkyl, substituted alkyl, straight alkyl, substituted straight alkyl, branched alkyl, substituted branched alkyl, straight alkenyl, substituted straight alkenyl, branched alkenyl, substituted branched alkenyl, straight alkynyl, substituted straight alkynyl, branched alkynyl, substituted branched alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclyl, substituted heterocyclyl, mono-unsaturated heterocyclyl, poly-unsaturated heterocyclyl, mono-substituted poly-unsaturated heterocyclyl, poly-substituted poly-unsaturated heterocyclyl, mono-substituted mono-unsaturated heterocyclyl, poly-substituted mono-unsaturated heterocyclyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl, wherein Y is different from a peptide or is absent.

  本发明涉及一种式（I），（II），（III），（IV），（V）的化合物：其中Z1，Z2，Z3和Z4分别独立地选自包括C（O）—，—C（S）—，—C（O）—NR10—，—C（S）—NR11—，—C（N—CN）—NR12—，—S（O）—，—S（O2）—，—S（O）—NR13—和S（O2）—NR14—，—O—，—S—或各自缺席的基团；X是间隔基团，独立地选自包括-M1-L1-K-L2-M2-，其中Y选自包括烷基，取代烷基，直链烷基，取代直链烷基，支链烷基，取代支链烷基，直链烯基，取代直链烯基，支链烯基，取代支链烯基，直链炔基，取代直链炔基，支链炔基，取代支链炔基，环烷基，取代环烷基，环烯基，取代环烯基，杂环基，取代杂环基，单不饱和杂环基，多不饱和杂环基，单取代多不饱和杂环基，多取代多不饱和杂环基，单取代单不饱和杂环基，多取代单不饱和杂环基，芳基，取代芳基，杂芳基和取代杂芳基，其中Y不同于肽或不存在。
• New compounds for the inhibition of rotamases and use thereof
  申请人：Jerini AG

  公开号：EP2100876A2

  公开（公告）日：2009-09-16

  The present invention is related to a compound of the formula (I): wherein Z1, Z2, Z3 and Z4 are each and independently selected from the group comprising - C(O)-, -C(S)-, -C(O)-NR10-, -C(S)-NR11-, -C(N-CN)-NR12-, -S(O)-, -S(O2)-, -S(O)-NR13-, and -S(O2)-NR14-, -O-, -S- or are each and individually absent; X is a spacer and is independently selected from the group comprising -M1-L1-K-L2-M2-, wherein Y is selected from the group comprising alkyl, substituted alkyl, straight alkyl, substituted straight alkyl, branched alkyl, substituted branched alkyl, straight alkenyl, substituted straight alkenyl, branched alkenyl , substituted branched alkenyl, straight alkynyl, substituted straight alkynyl, branched alkynyl, substituted branched alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heterocyclyl, substituted heterocyclyl, mono-unsaturated heterocyclyl, poly-unsaturated heterocyclyl, mono-substituted poly-unsaturated heterocyclyl, poly-substituted poly-unsaturated heterocyclyl, mono-substituted mono-unsaturated heterocyclyl, poly-substituted mono-unsaturated heterocyclyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl, wherein Y is different from a peptide or is absent.

  本发明涉及一种式 (I) 的化合物： 其中 Z1、Z2、Z3 和 Z4 各自独立地选自包括 -C(O)-、-C(S)-、-C(O)-NR10-、-C(S)-NR11-、-C(N-CN)-NR12-、-S(O)-、-S(O2)-、-S(O)-NR13- 和 -S(O2)-NR14-、-O-、-S- 或各自独立地不存在的组；X 是间隔物，独立地选自包括-M1-L1-K-L2-M2-在内的组，其中 Y 选自包括烷基、取代烷基、直链烷基、取代直链烷基、支链烷基、取代支链烷基、直链烯基、取代直链烯基、支链烯基、取代支链烯基、直链炔基、取代直链炔基、支链炔基、取代支链炔基、环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、取代环烷基、环烷基、取代环烷基、环烯基、取代环烯基、杂环烷基、取代杂环烷基、单不饱和杂环烷基、多不饱和杂环烷基、单取代多不饱和杂环烷基、多取代的多不饱和杂环基、单取代的单不饱和杂环基、多取代的单不饱和杂环基、芳基、取代的芳基、杂芳基和取代的杂芳基，其中 Y 不同于肽或不存在。